Abstract

This report describes a limited clinical trial in which a synthetic basic copolymer of amino acids has been used for multiple sclerosis (MS) therapy. This copolymer, denoted Cop 1, is composed of alanine, lysine, glutamic acid, and tyrosine, and is immunologically cross-reactive on the cellular level, with myelin basic protein (MBP), the encephalitogenic protein which induces acute experimental allergic encephalomyelitis (EAE) [9]. The rationale behind this study was the assumption that there is a resemblance between MS and EAE, and hence that a material capable of suppressing EAE might exert a beneficial effect in the case of MS as well.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.